Ultragenyx Pharmaceutical's GAAP loss for 2021 was $454.025 million, up 2.4 times from $186.566 million in the previous year. Revenue increased 29.7% to $351.406 million from $271.03 million a year earlier.
Ultragenyx Pharmaceutical's GAAP loss for 2021 was $454.025 million, up 2.4 times from $186.566 million in the previous year. Revenue increased 29.7% to $351.406 million from $271.03 million a year earlier. 
ir.ultragenyx.com
English (US) 